(Q45460371)

14 December 2017

title

Human APOBEC3G incorporation into murine leukemia virus particles (English)

1 reference

14 December 2017

1 reference

murine leukemia virus

object named as

murine leukemia virus

1 reference

Melanie Kremer

1

1 reference

14 December 2017

Alexandra Bittner

series ordinal

2

1 reference

14 December 2017

Barbara S Schnierle

series ordinal

3

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

14 December 2017

1 reference

14 December 2017

volume

337

1 reference

14 December 2017

issue

1

1 reference

14 December 2017

page(s)

175-182

1 reference

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

The interaction between HIV-1 Gag and APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

APOBEC3G targets specific virus species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

A transient three-plasmid expression system for the production of high titer retroviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Inhibition of hepatitis B virus replication by APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

APOBEC3G incorporation into human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.04.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.04.006

1 reference

14 December 2017

1 reference